Iradokizunak:
harm » farm (Hedatu)
resolve. » resolved. (Hedatu)
evolvedsddddsds. » resolvedsddddsds. (Hedatu)
evolved. » resolved. (Hedatu)
Erakusten 1 - 20 emaitzak -- 175 bilaketa honetara 'harm is (((((evolvedsddddsds. OR resolve.) OR resolve.) OR evolved.) OR involved.) OR involves.)', Bilaketaren denbora: 0,08s Findu emaitzak
  1. 1
    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl

    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl nork Elham Mazarei (4508746)

    Argitaratua 2025
    Gaiak:
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year).

    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year). nork Olga Amberger (20299807)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  13. 13
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  16. 16
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  18. 18
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study.

    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. nork Diana M. Hendrickx (1507435)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: